Intrexon Corp. (NYSE:XON) was down 3% on Monday . The stock traded as low as $24.30 and last traded at $25.34, with a volume of 2,037,426 shares. The stock had previously closed at $26.12.

Several equities research analysts recently weighed in on XON shares. Vetr raised Intrexon Corp. from a “hold” rating to a “strong-buy” rating and set a $33.69 price objective for the company in a report on Wednesday, August 3rd. Zacks Investment Research raised Intrexon Corp. from a “hold” rating to a “buy” rating and set a $29.00 price objective for the company in a report on Tuesday, July 19th. Stifel Nicolaus reissued a “buy” rating and issued a $57.00 price objective on shares of Intrexon Corp. in a report on Wednesday, June 29th. Wunderlich reissued a “buy” rating and issued a $50.00 price objective on shares of Intrexon Corp. in a report on Thursday, July 7th. Finally, Griffin Securities reissued a “buy” rating and issued a $55.00 price objective on shares of Intrexon Corp. in a report on Tuesday, August 16th. Three analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $41.71.

The company’s market cap is $2.96 billion. The company has a 50-day moving average price of $26.58 and a 200 day moving average price of $29.42.

Intrexon Corp. (NYSE:XON) last issued its quarterly earnings results on Tuesday, August 9th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by $0.16. The business earned $52.50 million during the quarter, compared to analyst estimates of $53.78 million. The firm’s quarterly revenue was up 17.0% on a year-over-year basis. During the same period last year, the firm posted ($0.37) EPS. Equities analysts predict that Intrexon Corp. will post ($1.36) earnings per share for the current fiscal year.

Intrexon Corporation (Intrexon) forms collaborations to create biologically based products and processes using synthetic biology. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.